Biosimilars Expensive medicines that can generate billions of dollars in sales for drugmakers and the US Supreme Court's decision to speed access to copycat biologic drugs has found an echo in India, with the Indian biogenerics industry poised to exploit the opportunity similar to the generics potential, reports The Pharma Letter’s India correspondent. 30 August 2017